文献速递泌尿男性生殖肿瘤

PEACE-3最终OS:恩扎卢胺联合镭-223一线治疗mCRPC

Final overall survival results from EORTC 1333/PEACE-3 trial of enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer.
PubMed 文献 · Ann Oncol · 2026-02-26

EORTC 1333/PEACE-3研究最终总生存分析显示,446例转移性去势抵抗性前列腺癌患者随机接受恩扎卢胺单药或联合六周期镭-223治疗。中位随访58个月、317例死亡时,联合组OS显著获益(HR 0.76,95%CI 0.60-0.96,P=0.0096),中位OS分别为38.2个月与32.6个月,rPFS的HR为0.71。

要点

  • 恩扎卢胺联合镭-223较单药显著改善mCRPC一线治疗的OS(HR 0.76)。
  • 联合组中位OS 38.2个月,单药组32.6个月。
  • 联合组≥3级TEAE升高,最常见为高血压。

核心结论

  • 最终分析证实恩扎卢胺联合镭-223较恩扎卢胺单药显著改善mCRPC一线治疗的rPFS和OS。

研究设计与样本

  • 患者随机接受恩扎卢胺单药(n=224)或恩扎卢胺联合六周期镭-223(n=222)。
  • 自2018年3月起所有患者强制联合骨保护剂。
  • 最终OS分析触发日期为2025年5月1日,中位随访58个月。

主要发现

  • 共报告317例死亡,OS的HR为0.76(95%CI 0.60-0.96,P=0.0096),达到预设显著性水平<0.0248。
  • 恩扎卢胺单药组中位OS为32.6个月(95%CI 29.3-38.2个月),联合组为38.2个月(95%CI 33.1-44.8个月)。
  • rPFS的HR为0.71(95%CI 0.57-0.89)。
  • 联合组≥3级治疗出现不良事件从57.6%升至69.3%,治疗相关≥3级TEAE从18.8%升至28.9%,最常见为高血压。

临床怎么用

  • 对于mCRPC一线治疗,可考虑恩扎卢胺联合六周期镭-223以改善rPFS和OS。
  • 联合治疗时须同时使用骨保护剂以减少骨骼并发症。
  • 需关注联合组更高的≥3级不良事件风险,尤其是高血压。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The primary analysis of the European Organisation for Research and Treatment of Cancer (EORTC) 1333/PEACE-3 study demonstrated that enzalutamide plus radium-223 (Ra223) improved radiological progression-free survival (rPFS) compared with enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC). The primary endpoint was rPFS, while overall survival (OS) was a key secondary endpoint. Interim OS results were reported at the time of primary analysis. Here, we report the final OS analysis. PATIENTS AND METHODS: From November 2015 to March 2023, 446 patients were randomly assigned to receive enzalutamide alone or enzalutamide combined with six cycles of Ra223. Co-administration of bone-protecting agents (BPAs) became mandatory for all patients from March 2018. Final analysis of OS was triggered on 1 May 2025. RESULTS: With a median follow-up of 58 months and 317 reported deaths, the hazard ratio (HR) was 0.76 [95% confidence interval (CI) 0.60-0.96, P = 0.0096] for OS in favor of the enzalutamide + Ra223 arm, reaching the predefined level of statistical significance of <0.0248. Median OS was 32.6 months (95% CI 29.3-38.2 months) in the enzalutamide arm (n = 224) and 38.2 months (95% CI 33.1-44.8 months) in the combination arm (n = 222). The HR for rPFS was 0.71 (95% CI 0.57-0.89). Grade ≥3 treatment-emergent adverse events (TEAEs) increased from 57.6% to 69.3% in the combination arm, as did treatment-related grade ≥3 TEAEs (18.8% versus 28.9%), with the most frequent being hypertension. CONCLUSIONS: The final analysis of this study confirmed that the combination of enzalutamide with Ra223 significantly improved not only rPFS but also OS as first-line therapy for mCRPC versus enzalutamide alone. Co-administration of a BPA is required to reduce skeletal complications.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Gillessen S, Gallardo E, Choudhury A, et al. Final overall survival results from EORTC 1333/PEACE-3 trial of enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer. Ann Oncol. 2026. PMID: 41763609. doi:10.1016/j.annonc.2026.02.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。